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Aim of the study: Recent studies 
showed relatively better outcome 
for children with refractory (refAML) 
and relapsed acute myeloid leukemia 
(relAML). Treatment of these patients 
has not been unified within Polish 
Pediatric Leukemia/Lymphoma Study 
Group (PPLLSG) so far. The goal of 
this study is to analyze the results 
of this therapy performed between 
2005–2011.
Material and methods: The outcome 
data of 16 patients with refAML and 
62 with relAML were analyzed retro-
spectively. Reinduction was usually 
based on idarubicine, fludarabine and 
cytarabine with allogenic hematopoi-
etic stem cell transplant (alloHSCT) in 
5 refAML and 30 relAML children.
Results: Seventy seven percent relAML 
patients entered second complete re-
mission (CR2). Five-year OS and dis-
ease-free survival (DFS) were estimat-
ed at 16% and 30%. The outcome for 
patients after alloHSCT in CR2 (63%) 
was better than that of those not 
transplanted (36%) with 5-year OS of 
34% vs. 2-year of 7% and 5-year DFS 
of 40% vs. 12.5%. Second complete 
remission achievement and alloHSCT 
were the most significant predictors 
of better prognosis (p = 0.000 and 
p = 0.024). The outcome of refAML 
children was significantly worse than 
relAML with first remission (CR1) rate 
of 33%, OS and DFS of 25% at 3 years 
and 53% at 2 years, respectively. All 
survivors of refAML were treated with 
alloHSCT after CR1.
Conclusions: The uniform reinduction 
regimen of the documented efficacy 
and subsequent alloHSCT in remis-
sion is needed to improve the out-
come for ref/relAML children treated 
within PPLLSG. The focus should be 
on the future risk-directed both front 
and second line AML therapy.
Key words: acute myeloid leukemia, 
relapse, stem cell transplantation, chil-
dren.
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Introduction
Childhood acute myeloid leukemia (AML) is resistant to therapy (refAML) 
in 5–10% or recurs (relAML) in 30–40% of patients [1, 2]. Recent trials have 
shown a higher cure rate, providing an insight into current therapeutic strat-
egies for these children with poor prognosis [3, 4].
Treatment of ref/relAML children within the Polish Pediatric Leukemia/
Lymphoma Study Group (PPLLSG) has not been unified so far. The improved 
outcome among consecutive BFM AML studies encouraged the PPLLSG to 
adopt the modified BFM relapsed AML 2001/01 protocol [5]. The objective of 
this retrospective report is to analyze the outcomes to date in comparison 
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with other groups and to establish a benchmark for analy-
sis of future therapy.
Material and methods
Between 2005 and 2011, 16 children (8 boys, 8 girls) 
with refAML and 62 children (38 boys, 24 girls) with relAML 
were treated at PPLLSG institutions.
The median time from the date of the first complete 
remission (CR1) to relapse was 10 months (range 1–77.4). 
Forty (64%) relAML patients had early (≤ 1 year) and 22 
(35%) late relapse (> 1 year). Table 1 shows the characteris-
tics of the patients in this cohort.
Reinduction treatment
Informed consent and ethical approval were obtained 
before the therapy was performed. There was no single 
reinduction chemotherapy performed. The management 
varied according to different institutions. IdaFlag (fludar-
abine, high-dose cytarabine and granulocyte colony-stim-
ulating factor with addition of idarubicin) was the most 
common basis of the administered regimens: refAML n = 11, 
relAML n = 43.
After reinduction chemotherapy, 35 (5 refAML, 30 
relAML) patients underwent allogeneic hematopoiet-
ic stem cell transplantation (alloHSCT): 24 (68%) from 
a matched unrelated donor (MD), 5 (14%) from a matched 
sibling donor (MSD), 3 (8%) from a mismatched donor 
(MMD), 1 (3%) from a haploidentical donor, and for 2 (6%) 
there were no data concerning donor type. The majority of 
children were conditioned for alloHSCT with the busulfan 
plus cyclophosphamide-based regimen.
Definitions
Primary refAML, first relapse AML, and risk group at the 
initial diagnosis were defined according to the AML-BFM 
Interimphase 2004 protocol. Early treatment response, 
postreinduction complete remission and second relapse 
were defined according to the Relapsed AML 2002/01 pro-
tocol [5].
Statistical analysis
Surviving patients were censored on the 31st of Decem-
ber 2011. For statistical analysis, the Kaplan-Meier and the 
log-rank test were used. The Cox proportional-hazards 
regression model allowed us to determine significant 
time-dependent factors. Results were considered to be 
statistically significant if the p value was under 0.05.
Results
Primary refAML outcome
Of 16 children, one patient died before reinduction. Fif-
teen (93%) children underwent reinduction chemotherapy 
and the early good response rate was 40% (n = 6). Five 
(33%) children, including one poor early responder, en-
tered first complete remission.
Of the patients who remitted, one had a relapse 9 days 
after CR1 and died 3.5 months later. Four remaining pa-
tients underwent alloHSCT at a median of 1.5 months 
(range 1.1–1.9) from CR1.
One of the transplanted children relapsed after MSD 
alloHSCT. The three remaining grafted patients (2 MD, 
1 MSD) were the only survivors at the time of the last fol-
low-up (Table 2).
One child who failed to enter CR1 on second-line che-
motherapy received matched unrelated donor (MUD) al-
loHSCT and died 9 days later of progressive disease. By 
December 31, 2011, three (18.7%) of 16 refAML children, 
including 1 poor early responder, were alive, with a median 
time from CR1 of 33.2 months (range 14.9–34.2).
Relapse AML outcome
Four children died before reinduction. Among the 58 
patients who received chemotherapy, 37 (63%) were good 
early responders with missing data in 14 cases. Second 
complete remission (CR2) was attained in 44 (75%) chil-
dren, including 5 poor early responders. One other patient 
achieved CR2 after MD alloHSCT performed in relapse, re-
sulting in a CR2 rate of 77% (n = 45). The CR2 rate among 
children treated initially according to protocols AML-BFM 
2004 Interim and ANLL98 was 70% (n = 35) and 88% (n = 8) 
respectively.
AlloHSCT was performed in 28 (63%) children in CR2, 
at median time of 2.5 months (range 0.2–5.5) from second 
Table 1. Characteristics of the disease and the patients with refAML 
and refAML
Primary refractory 
AML (n = 16)
First relapse 
AML (n = 62)
Age
1.2–17.1 years 
(median 12.7)
0.1–17.5 years 
(median 10.9)
Risk group at primary 
diagnosis
     SR
     HR 16 (100%)
17 (27%)
45 (72%)
Initial protocol
    AML-BFM 2004 Interim
    ANLL98
15 53 
9
Site of primary disease/
relapse
    isolated BM
    BM + CNS
    BM + other
    isolated CNS
    other isolated
13
2
1
43
10
4
4
1
Table 2. Treatment follow-up in children with refAML after CR1 
according to the consolidation with alloHSCT
AlloHSCT after CR1 
(n = 4)
No alloHSCT after CR1 
(n = 1)
Death/TRM
Relapse n = 1,  26 months* n = 1,  0.3 months*
Survival in CR1
n = 3,  33.2 months** 
(range 14.9–34.2)
*time from CR1 in months; **median time from CR1
50 contemporary oncology
remission. Of 44 children in CR2 after reinduction chemo-
therapy, 16 (36%) did not undergo alloHSCT. Table 3 shows 
the follow-up of the children in CR2, according to the sub-
sequent alloHSCT therapy.
Among the transplanted children 8 died of toxic com-
plications – 3 due to graft-versus-host disease, 2 due to 
multiorgan failure, and one each from sepsis, CNS hem-
orrhage, and lymphoproliferative disease. In 6 non-trans-
planted patients treatment-related mortality was caused 
by multiorgan failure, sepsis and CNS hemorrhage in 3, 2 
and one case respectively.
Two children received MD alloHSCT in relapse resulting 
in one CR2 attained. Both of them died, one due to hemor-
rhagic complications in CR2, the other because of progres-
sive disease, 47 and 37 days from alloHSCT respectively.
By December 31, 2011, 16 (35%) of 62 relAML children, 
including 1 poor early responder1 and 3 non-grafted pa-
tients, were alive, with a median time from CR2 of 30.4 
months (range 0.03–87.6). One of the non-transplanted 
survivors was a 17-year-old boy with SR AML FAB M4 inv16, 
with 2 years CR1 duration. The other one was a 2-year-old 
boy at diagnosis, with AML FAB M4E, delayed CR1 (HR), 
early CNS relapse, and a good response to one Flag course 
and CNS radiotherapy. The third one was a 15-year-old boy 
with HR AML BCR/ABL positive (FAB data missing), late 
marrow relapse, and remission entry after IdaFlag plus da-
satinib. The time of follow-up of these 3 boys was 0.6, 32 
and 4 months respectively.
Table 4 shows the comparison of the therapy results in 
refAML and relAML.
Prognostic factors
The impact of selected prognostic factors (age, risk 
group, early response to chemotherapy, duration of CR1, 
HSCT in relapse) for CR2 rate and survival was analyzed in 
the group of relAML.
Early relapse was significantly correlated with lower re-
mission rates (62% vs. 90% P = 0.046; Table 5) and both 
5-year pDFS (P
log-rank
 = 0.03) and pOS (P
log-rank
 = 0).
There was a marginally significant difference in overall 
survival between high and standard risk patients (P
log-rank
 
= 0.035). A significant effect of alloHSCT on survival was 
identified in the log-rank test (pDFS: P
log-rank
 = 0.02; pOS: 
P
log-rank
 = 0).
In a Cox regression model using age, risk group, CR1 
duration, achievement of CR2 and HSCT in relapse, only 
HSCT after CR2 showed a strong impact on survival (Tables 
6 and 7; Fig. 1).
The variety of postreinduction chemotherapy regimens 
used in our group precludes the evaluation of the impact 
of any one therapeutic schedule.
Discussion
The 5-year OS of 16% for children with relAML in this re-
port reflects the poor prognosis for these patients. The sur-
vival rates in childhood relAML have increased over time 
with intensified and uniform reinduction concepts and 
improved supportive care. They range from 12% to 34% at 
2–5 years in other studies [6] with recent relatively good 
outcome of 38% at 4 years in Relapsed BMF AML 2001/01 
and 38% at 5 years in Nordic Society for Pediatric Hema-
tology and Oncology (NOPHO) AML93 trials [3, 5]. Results 
presented here fit the lower range of these limits but the 
comparability may not be accurate due to methodological 
discrepancies between the trials.
Whereas the survival of the patients in the presented 
cohort was unsatisfactory, the second remission rate of 
77% was comparable with those shown by the leading 
Table 3. Treatment follow-up of relAML children in CR2, according to the consolidation with alloHSCT
AlloHSCT in CR2;
median time to HSCT: 2.5 mo (range 0.2–55)
No alloHSCT in CR2
Number of patients 28 16
Age 0.2–17.4 years (median 8.9) 0.1–17.3 years (median 11.3)
Boys/girls 13/15 10/6
Death/TRM 8 (28%) 1.7 months* (range 0.4–12) 6 (37%) 2.1 months* (range 0.7–7)
Second relapse 7 (25%) 10 months* (range 5–16) 7 (43%) 2 months* (range 0.6–3.2)
Survival in CR2 13 (46%) 30.4 months* (range 4.6–87.6) 3 (18%) 30.4 months* (range 0.03–32)
pDFS
5 years 0.408 ±0.104 5 years 0.125 ±0.083
log rank 0.002
pEFS
5 years 0.352 ±0.104 2 years 0.074 ±0.103
log rank = 0.000
pOS
5 years 0.348 ±0.16 median follow up 20.2 mo 
(range 3.5–88.3)
2 years 0.073 ±0.07 median follow up 4 mo  
(range 0.6–32.7)
log rank 0.000
*median time from CR2
1One poor early responder, who entered and remained in CR2 on the last follow-up, afterwards had the next relapse.
51
Outcome of refractory and relapsed acute myeloid leukemia in children treated during 2005–2011 – experience of the Polish Pediatric 
Leukemia/Lymphoma Study Group (PPLLSG)
groups: 77% (NOPHO) [3], 71% (French Leucémie Aique 
Myeloide Enfant 89/91 protocol-LAME) [4]. This observa-
tion can be explained with the low quality of the remis-
sions and directs the attention toward the need for op-
timal chemotherapy choice. Prospective monitoring of 
minimal residual disease (MRD) is supposed to be a more 
accurate technique to evaluate the disease status than re-
mission rate [1, 9].
In accordance with other reports, in the presented group 
the second remission rate and survival differed according 
to the first remission duration [3, 4, 7, 8, 13]. Early relapse 
was associated with a statistically significantly lower CR2 
rate (62% vs. 90%) and worse 5-year pOS (11% vs. 27%) 
than late relapse. Presented survival in early relapse was 
similar to 3-year pOS of 24% in the MRC AML10 trial; how-
ever, NOPHO 93 and LAME 89/91 studies reported 21% and 
24% at 5 years.
The prognosis in the analyzed refAML group was dis-
mal, with CR1 rate, disease-free survival (DFS), event-free 
survival (EFS) and overall survival (OS) of 33%, 53% at 
2 years, 16% at 3 years and 25% at 3 years vs. 77%, 30% at 
5 years, 17% at 5 years and 16% at 5 years in relAML respec- 
tively. In contrast to relAML, among the presented 16 chil-
dren with refAML, no one had standard risk AML, the CR1 
rate was half the level of the CR2 rate in relAML, and the 
final prognosis was much worse. These findings show that 
probably refAML should be evaluated as a distinct entity.
There are few reports describing treatment outcomes 
in cohorts of children with refAML. Of 11 refAML patients 
in the DCOG study, no one attained CR1 [6]. Gorman et al. 
reported 2-year DFS of 0% in a group of 7 refAML children 
[10]. Due to the small numbers, these children are incor-
porated into cohorts of relAML or poor responder AML pa-
tients. Warenham et al. have just reported (NOPHO-AML 
2004) the outcome of early alloHSCT in 14 refAML patients. 
Two of them were transplanted in persistent disease and 
9 with positive MRD. These 11 patients became long-term 
survivors (3-year follow-up), recommending early alloHSCT 
regardless of the disease state in such cases [11].
In the presented ref/relAML cohort, patients who were 
transplanted in postreinduction remission had the best 
prognosis and accounted for 100% of refAML and 84% 
of relAML survivors. AlloHSCT in CR2 was statistically the 
leading predictor of better outcome in relAML children. 
This is consistent with the literature data [3, 4, 7, 10] and 
the documented graft versus leukemia effect which is the 
basis of the established consensus to advocate alloHSCT 
to all ref/relAML patients in postreinduction remission [1, 
2]. This therapy gives the chance of 5-year survival of up 
to 49–62% in different studies [12], compared with 35% 
in the presented cohort. It shows that details of the trans-
plant procedure, toxicities and supportive care modalities 
should be analyzed, which is planned to be done in a sep-
arate paper.
In the analyzed study the median time between CR2 
and second relapse or treatment-related death in the 
non-transplanted patients was 2 and 2.1 months respec-
tively. These time periods were shorter than the median 
time to transplant (2.5 months) in the grafted children. It 
suggests that these circumstances precluded HSCT and 
Table 4. Summary of outcome and follow-up of children with refAML and relAML
refAML (n = 16) relAML (n = 62)
Postreinduction
CR rate
n = 5 (33%) n = 45 (77%)
First/second relapse n = 2/5 (0.3 and 26 months)* n = 14/45 (31%) 16.4 months (range 0.6–16.4)**
Survival in CR1/CR2 n = 3/5 33.2 months (range 17.8–34.2)** n = 16/45 (35%) 30.4 months (range 0.03–87.6)**
pDFS 2 years, 0.533 ±0.248 5 years, 0.305 ±0.07 
pEFS 3 years, 0.167 ±0.093 5 years, 0.177 ±0.05 
pOS
3 years, 0.25 ±0.108
median follow-up
37.3 months (range 17.8–37.4)
5 years, 0.164 ±0.079 
median follow-up
19.8 months (range 0.6–88.3)
*time from remission; **median time from remission
HSCT – hematopoietic stem cell transplantation 
Fig. 1. Probability of survival according to consolidation in CR2
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shows the need for optimal care to avoid delay in proceed-
ing to transplant.
The question may be raised whether further relapses 
are due to delay of HSCT or to a more aggressive type of 
leukemia or suboptimal first line treatment. On the other 
hand, favorable long-term outcomes after chemotherapy 
alone have also been reported. Goemans et al. in 2008 
summarized from the literature 34 of them [6]. In our co-
hort there was one survivor with 32 months of follow-up 
after chemotherapy alone.
Genetic profiling and MRD monitoring are currently 
the modalities which, if performed after primary diagno-
sis, might provide insight into these doubts concerning 
AML heterogeneity. Specific genetic predictors and MRD 
strongly correlate with the treatment outcome [1, 2, 9] 
and may guide risk-stratified therapeutic decisions. The 
impact of the genetic characteristics on the management 
individualization was shown in the Relapsed AML 2001/01 
trial. The patients with core binding factor acute myeloid 
leukemia (CBF-AML) treated with DaunoFlag had an OS of 
82% at 4 years in contrast to 58% in those treated with 
FLAG only [5]. This risk-directed strategy may also be ex-
tended to the frontline AML therapy as it is proposed in 
the AML-BFM 2012 study: whereas HSCT in children in CR1 
has been considered controversial so far, in this trial it is 
offered to subgroups with unfavorable genetics, assuming 
relapse rate reduction [1, 13].
In our nationwide study none of the refAML patients 
and nearly none of relAML ones presented the potential 
to survive a long time without HSCT in postreinduction 
Table 5. Evaluation of the impact of selected prognostic factors on CR2 rate in relAML children
Factor n CR2 (n = 44)
Univariate analysis
   z                                  p
age
< 10 years
> 10 years
27
35
70%
74%
0.205106 0.837489
risk group
SR
HR
17
45
94%
64%
1.51033 0.130960
early response
< 20%
> 20%
37
7
83%
71%
0.223753 0.822950
CR1 duration
≤ 1 year
> 1 year
40
22
62%
90%
1.99513 0.046030
Table 6. Evaluation of the impact of selected prognostic factors on DFS in relAML children
Factor N pDFS log-rank
Cox regression
    HR (95%CI)                      p
age
< 10 years
≥ 10 years
19
26
 5 years, 0.307 ±0.113
 5 years, 0.305 ±0.094
 0.709  1.578  0.323692
risk group
SR
HR
16
34
 5 years, 0.499 ±0.13
 5 years, 0.218 ±0.078
 0.153  2.328  0.083611
CR1 length
≤ 1 year
> 1 year
25
20
 5 years, 0.24 ±0.08
 5 years, 0.382 ±0.122
 0.030  0.465  0.104055
HSCT after CR2
HSCT
no HSCT
28
16
 5 years, 0.408 ±0.083
 2 years, 0.125 ±0.083
 0.002  2.751  0.01458
Table 7. Evaluation of the impact of selected prognostic factors on OS in relAML children
Factor n pOS log-rank
Cox regression 
     HR (95%CI)                     p
age
< 10 years
≥ 10 years
27
35
 5 years, 0.258 ±0.096
 5 years, 0.121 ±0.095
0.502 1.962 0.057
risk group
SR
HR
17
45
 5 years, 0.238 ±0.184
 5 years, 0.182 ±0.063
0.035 2.119 0.090
CR1 length
< 1 year
≥ 1 year
40
22
 5 years, 0.119 ±0.057
 5 years, 0.272 ±0.202
0.000 1.44 0.467
CR2
CR2
no CR2
45
17
 5 years, 0.228 ±0.108
 0.48 year 0 ±0
0.000 5.326 0.000
HSCT
HSCT
no HSCT
30
32
 5 years, 0.324 ±0.150
 2 years, 0.070 ±0.047
0.000 2.989 0.024
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remission. The key issue of current management of ref/
relAML is the reinduction regimen to achieve and main-
tain remission and optimal care to support the patient for 
early HSCT using the best genomic typing technology to 
select the best matched available donor [1, 2]. There is no 
standard reinduction chemotherapy protocol [1, 2]. The 
concern should focus on the optimal balance between ef-
ficacy and toxicity of the chosen regimen and the unified 
rules of the therapy which allow to derive conclusions on 
future solutions. The development of highly sensitive MRD 
techniques standardized for all patients, genetic profiling 
and identification of other predictors are required for fu-
ture more individualized treatment.
Authors declare no conflict of interest.
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